Eloralintide, a selective, longacting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept Bhattachar 2026 Diabetes, Obesity and Metabolism Wiley Online Library The evolving landscape of obesity pharmacotherapy Nature Reviews Drug Discovery, 2026 1 Obesity pharmacotherapy has moved from weight loss drugs to cardiometabolic disease modifying therapy Obesity is now framed as a chronic, relapsing, Everyone and their mother is talking about eloralintide, the new amylin receptor agonist showing up to 20% body weight reduction in early trials. Gabriel Alizaidy, MD, MS Buy Cagrilintide 5mg 10mg Third Party Tested BioEdge Peptides Eloralintide vs #Cagrilintide Which #Amylin Agonist is Better? YouTube